Australia is closely watching the arrival of retatrutide, a cutting-edge dual GIP and GLP-1 receptor agonist , representing a significant advance in obesity treatment . Early research findings have demonstrated https://giant-e-bikes530330.wikiconversation.com/8486227/new_treatment_in_australia_a_new_hope_for_reducing_body_weight